Picture of Agentix logo

AGTX Agentix Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

Momentum

Relative Strength (%)
1m-37.3%
3m-3.63%
6m-61.64%
1yr-74.07%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Mar 202431st Mar 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Agentix EPS forecast chart

Profile Summary

Agentix Corp. is a clinical-stage biotechnology company. The Company is engaged in developing therapeutic agents for the treatment of metabolic diseases like Type 2 diabetes mellitus, obesity, non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its pipeline includes AGTX-2004 and AGTX-2003. AGTX-2004 is a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of obesity and type 2 diabetes mellitus (T2DM). AGTX-2003 is a peripherally-acting CB1 receptor inverse agonist that has demonstrated efficacy in animal models of obesity and non-alcoholic fatty liver disease. The Company is focused on the development of synthetic agonists, inverse agonists, and antagonists, which modulate the endocannabinoid system (ECS). The ECS is the regulatory system which governs metabolism. The Company’s wholly owned subsidiaries include GSL Healthcare, Inc., Agentix Australia Pty Ltd, and Applied Biopharma LLC.

Directors

Last Annual
March 31st, 2023
Last Interim
December 31st, 2023
Incorporated
April 18th, 2013
Public Since
August 5th, 2015
No. of Shareholders
226
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
40,066,931

AGTX Share Price Performance

Upcoming Events for AGTX

Q4 2023 Agentix Corp Earnings Release

Q1 2024 Agentix Corp Earnings Release

Similar to AGTX

Picture of Acacia Diversified Holdings logo

Acacia Diversified Holdings

us flag iconPink Sheets on Nasdaq

Picture of Acusphere logo

Acusphere

us flag iconPink Sheets on Nasdaq

Picture of Adorbs logo

Adorbs

us flag iconPink Sheets on Nasdaq

Picture of Agrios Global Holdings logo

Agrios Global Holdings

us flag iconPink Sheets on Nasdaq

Picture of Aida Pharmaceuticals logo

Aida Pharmaceuticals

us flag iconPink Sheets on Nasdaq

FAQ